<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944033</url>
  </required_header>
  <id_info>
    <org_study_id>β2-agonist</org_study_id>
    <nct_id>NCT01944033</nct_id>
  </id_info>
  <brief_title>β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation</brief_title>
  <official_title>β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectiveness of β2-agonists in the treatment of exacerbations of COPD is already
      established. The purpose of this study is to compare the effectiveness of the β2-agonists
      alone in nebulization with the association β2-agonists + Ipratropium bromide in the treatment
      of an acute exacerbation of COPD consulting the emergency departement based on the clinical
      and arterial blood gas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective study and randomized performed in patients admitted to the emergency
      departement for acute exacerbation of COPD. The patients were divided in two groups: Group
      Terbutaline/Ipratropium Bromide; received Terbutaline + Ipratropium bromide in nebulization
      and Group Terbutaline received Terbutaline alone in nebulization)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hospital admission rate and ICU admission rate</measure>
    <time_frame>within 24 hours after ED admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>dyspnea score</measure>
    <time_frame>24 hours after ED admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotracheal intubation rate</measure>
    <time_frame>within 24 hours after ED admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Acute Exacerbation of Chronic Obstructive Airways Disease</condition>
  <arm_group>
    <arm_group_label>Group Terbutaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Terbutaline/IB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bricanyl/Iprovent</intervention_name>
    <description>5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol</description>
    <arm_group_label>Group Terbutaline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bricanyl</intervention_name>
    <description>5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol</description>
    <arm_group_label>Group Terbutaline/IB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have known or suspected COPD based on pulmonary function test, arterial blood gas,
             clinical history, physical examination, and chest radiograph

          -  Age over 18 years old.

          -  COPD Exacerbation: sustained worsening of patient's condition from stable state
             necessitating change in regular medication within the last two weeks and need for non
             invasive ventilation with regard to arterialo blood gas abnormalities: PaCO2 &gt; 45
             mmHg, PH&lt;7,35 SaO2&lt;90%

        Exclusion Criteria:

          -  GCS ≤ 14

          -  hypersensitivity to anticholinergic

          -  severe acidosis

          -  immediate need for intubation

          -  lack of patient cooperation

          -  serious hemodynamic unstability or systolic blood pressure &lt; 90 mmHg, heart arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>semir nouira, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Monastir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Monastir</name>
      <address>
        <city>Monastir,</city>
        <state>Monastir</state>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fattouma Bourguiba University Hospital</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Pr. Semir Nouira</investigator_full_name>
    <investigator_title>Semir Nouira</investigator_title>
  </responsible_party>
  <keyword>β2-agonist</keyword>
  <keyword>Ipratropium Bromide</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease Exacerbation</keyword>
  <keyword>Emergency departement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

